These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 28664672)

  • 41. Response to 'Commentary to "Evaluation of a new motion correction algorithm in PET/CT: combining the entire acquired PET data to create a single three-dimensional motion-corrected PET/CT image."'.
    Minamimoto R
    Nucl Med Commun; 2016 Aug; 37(8):888. PubMed ID: 27348243
    [No Abstract]   [Full Text] [Related]  

  • 42. Commentary to 'Evaluation of a new motion correction algorithm in PET/CT: combining the entire acquired PET data to create a single three-dimensional motion-corrected PET/CT image'.
    Havariyoun G
    Nucl Med Commun; 2016 Aug; 37(8):888. PubMed ID: 27348242
    [No Abstract]   [Full Text] [Related]  

  • 43. Using a coaxial technique with a curved inner needle for CT-guided fine-needle aspiration biopsy.
    Gupta S; Ahrar K; Morello FA; Wallace MJ; Madoff DC; Hicks ME
    AJR Am J Roentgenol; 2002 Jul; 179(1):109-12. PubMed ID: 12076915
    [No Abstract]   [Full Text] [Related]  

  • 44. Relationship between tumor area, tumor volume, and criteria of response in clinical trials.
    Clamon G; Clamon L
    J Clin Oncol; 1993 May; 11(5):1005. PubMed ID: 8487042
    [No Abstract]   [Full Text] [Related]  

  • 45. Parasitic blood supply of neoplasms. Mechanisms and significance.
    Sprayregen S
    Radiology; 1973 Mar; 106(3):529-35. PubMed ID: 4346370
    [No Abstract]   [Full Text] [Related]  

  • 46. Real time 3D (4D) ultrasound-guided percutaneous biopsy of solid tumours.
    Albrecht H; Stroszczynski C; Felix R; Hünerbein M
    Ultraschall Med; 2006 Aug; 27(4):324-8. PubMed ID: 16710817
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A validation of the parametric assessment of the time of clonogen progression by simulation modelling].
    Ivankov AA; Tsodikov AD; Iakovlev AIu
    Vopr Onkol; 1993; 39(4-6):220-5. PubMed ID: 7975401
    [No Abstract]   [Full Text] [Related]  

  • 48. PET/CT-guided interventions: Indications, advantages, disadvantages and the state of the art.
    Cazzato RL; Garnon J; Shaygi B; Koch G; Tsoumakidou G; Caudrelier J; Addeo P; Bachellier P; Namer IJ; Gangi A
    Minim Invasive Ther Allied Technol; 2018 Feb; 27(1):27-32. PubMed ID: 29168421
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular imaging to improve radiotherapy.
    Price P
    Radiother Oncol; 2006 Mar; 78(3):233-5. PubMed ID: 16476496
    [No Abstract]   [Full Text] [Related]  

  • 50. [Prediction of Cancer Treatment Response by Physiologic and Metabolic Imaging].
    Matsumoto S
    Yakugaku Zasshi; 2016; 136(8):1101-5. PubMed ID: 27477724
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Therapeutic use of 198Au-comisol].
    Prikhod'ko AG; Rodzil'skiĭ SI; Tkachenko GI; Sheptun AN; Sorokin IN
    Med Radiol (Mosk); 1986 Oct; 31(10):18-23. PubMed ID: 3022100
    [No Abstract]   [Full Text] [Related]  

  • 52. Ultrasound imaging of apoptosis. DNA-damage effects visualized.
    Czarnota GJ; Kolios MC; Hunt JW; Sherar MD
    Methods Mol Biol; 2002; 203():257-77. PubMed ID: 12073448
    [No Abstract]   [Full Text] [Related]  

  • 53. Measure once or twice -- does it really matter?
    Hilsenbeck SG; Von Hoff DD
    J Natl Cancer Inst; 1999 Mar; 91(6):494-5. PubMed ID: 10088614
    [No Abstract]   [Full Text] [Related]  

  • 54. What Is the Natural History of Asymptomatic Pseudotumors in Metal-on-metal THAs at Mid-term Followup?
    Konan S; Duncan CP; Masri BS; Garbuz DS
    Clin Orthop Relat Res; 2017 Feb; 475(2):433-441. PubMed ID: 27444034
    [TBL] [Abstract][Full Text] [Related]  

  • 55. "Comet tail sign": A pitfall of post-gadolinium magnetic resonance imaging findings for metastatic brain tumors.
    Mitsuya K; Nakasu Y; Narita Y; Nakasu S; Ohno M; Miyakita Y; Abe M; Ito I; Hayashi N; Endo M
    J Neurooncol; 2016 May; 127(3):589-95. PubMed ID: 26839020
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion.
    Kim YS; Lee WJ; Rhim H; Lim HK; Choi D; Lee JY
    AJR Am J Roentgenol; 2010 Sep; 195(3):758-65. PubMed ID: 20729457
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Why RECIST works and why it should stay--reply to counterpoint.
    Sharma MR; Maitland ML; Ratain MJ
    Cancer Res; 2012 Oct; 72(20):5158. PubMed ID: 22952220
    [No Abstract]   [Full Text] [Related]  

  • 58. [Comprehensive cancer centers in Germany: role of radiology].
    Kauczor HU
    Rofo; 2005 Mar; 177(3):317-20. PubMed ID: 15719291
    [No Abstract]   [Full Text] [Related]  

  • 59. [Measurement of tumor volume by x-ray computed tomography in evaluating the response to treatment].
    Lérier O; Clément R; Juin P
    J Radiol; 1988 Nov; 69(11):651-6. PubMed ID: 3236290
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Response evaluation criteria in solid tumours (RECIST): problems and need for modifications in paediatric oncology?
    McHugh K; Kao S
    Br J Radiol; 2003 Jul; 76(907):433-6. PubMed ID: 12857700
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.